Therapeutic options for postmenopausal female sexual dysfunction

F. Al-Azzawi, J. Bitzer, U. Brandenburg, C. Castelo-Branco, A. Graziottin, P. Kenemans, M. Lachowsky, S. Mimoun, R. E. Nappi, S. Palacios, A. Schwenkhagen, J. Studd, K. Wylie, H. P. Zahradnik

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

BackgroundFemale sexual dysfunction (FSD) is a multidimensional problem combining biological, psychological and interpersonal elements of multiple etiologies. Menopause-related sexual dysfunction may not be reversible without therapy. Hormonal deficiency does not usually decrease in severity over time. Many options are available for the successful treatment of postmenopausal FSD. ObjectiveTo review the pharmacological and non-pharmacological therapies available for postmenopausal FSD, focusing on practical recommendations for managing postmenopausal women with sexual complaints, through a literature review of the most relevant publications in this field. Psychosocial therapyThis type of therapy (basic counselling, physiotherapy and psychosexual intervention) is considered an adaptable step-by-step approach for diagnostic and therapeutic strategies, normally combined with biomedical interventions to provide optimal outcomes. Pharmacological therapyFor postmenopausal FSD, many interventional options are now available, including hormonal therapies such as estrogens, testosterone, combined estrogen/testosterone, tibolone and dehydroepiandrosterone. Conclusion sMenopause and its transition represent significant risk factors for the development of sexual dysfunction. FSD impacts greatly on a patient's quality of life. Consequently, it is receiving more attention thanks to the development of effective treatments. Non-pharmacological approaches should be used first, focusing on lifestyle and psychosexual therapy. If required, proven effective hormonal and non-hormonal therapeutic options are available.

Original languageEnglish
Pages (from-to)103-120
Number of pages18
JournalClimacteric
Volume13
Issue number2
DOIs
Publication statusPublished - Apr 2010

Fingerprint

tibolone
Therapeutics
Testosterone
Estrogens
Pharmacology
Sexual Development
Dehydroepiandrosterone
Menopause
Publications
Life Style
Counseling
Quality of Life
Psychology

Keywords

  • Deficiency
  • Estrogen
  • Female sexual dysfunction
  • Menopause
  • Psychosocial
  • Testosterone

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Al-Azzawi, F., Bitzer, J., Brandenburg, U., Castelo-Branco, C., Graziottin, A., Kenemans, P., ... Zahradnik, H. P. (2010). Therapeutic options for postmenopausal female sexual dysfunction. Climacteric, 13(2), 103-120. https://doi.org/10.3109/13697130903437615

Therapeutic options for postmenopausal female sexual dysfunction. / Al-Azzawi, F.; Bitzer, J.; Brandenburg, U.; Castelo-Branco, C.; Graziottin, A.; Kenemans, P.; Lachowsky, M.; Mimoun, S.; Nappi, R. E.; Palacios, S.; Schwenkhagen, A.; Studd, J.; Wylie, K.; Zahradnik, H. P.

In: Climacteric, Vol. 13, No. 2, 04.2010, p. 103-120.

Research output: Contribution to journalArticle

Al-Azzawi, F, Bitzer, J, Brandenburg, U, Castelo-Branco, C, Graziottin, A, Kenemans, P, Lachowsky, M, Mimoun, S, Nappi, RE, Palacios, S, Schwenkhagen, A, Studd, J, Wylie, K & Zahradnik, HP 2010, 'Therapeutic options for postmenopausal female sexual dysfunction', Climacteric, vol. 13, no. 2, pp. 103-120. https://doi.org/10.3109/13697130903437615
Al-Azzawi F, Bitzer J, Brandenburg U, Castelo-Branco C, Graziottin A, Kenemans P et al. Therapeutic options for postmenopausal female sexual dysfunction. Climacteric. 2010 Apr;13(2):103-120. https://doi.org/10.3109/13697130903437615
Al-Azzawi, F. ; Bitzer, J. ; Brandenburg, U. ; Castelo-Branco, C. ; Graziottin, A. ; Kenemans, P. ; Lachowsky, M. ; Mimoun, S. ; Nappi, R. E. ; Palacios, S. ; Schwenkhagen, A. ; Studd, J. ; Wylie, K. ; Zahradnik, H. P. / Therapeutic options for postmenopausal female sexual dysfunction. In: Climacteric. 2010 ; Vol. 13, No. 2. pp. 103-120.
@article{50b66185c1dd4655b7ffa10d5165530b,
title = "Therapeutic options for postmenopausal female sexual dysfunction",
abstract = "BackgroundFemale sexual dysfunction (FSD) is a multidimensional problem combining biological, psychological and interpersonal elements of multiple etiologies. Menopause-related sexual dysfunction may not be reversible without therapy. Hormonal deficiency does not usually decrease in severity over time. Many options are available for the successful treatment of postmenopausal FSD. ObjectiveTo review the pharmacological and non-pharmacological therapies available for postmenopausal FSD, focusing on practical recommendations for managing postmenopausal women with sexual complaints, through a literature review of the most relevant publications in this field. Psychosocial therapyThis type of therapy (basic counselling, physiotherapy and psychosexual intervention) is considered an adaptable step-by-step approach for diagnostic and therapeutic strategies, normally combined with biomedical interventions to provide optimal outcomes. Pharmacological therapyFor postmenopausal FSD, many interventional options are now available, including hormonal therapies such as estrogens, testosterone, combined estrogen/testosterone, tibolone and dehydroepiandrosterone. Conclusion sMenopause and its transition represent significant risk factors for the development of sexual dysfunction. FSD impacts greatly on a patient's quality of life. Consequently, it is receiving more attention thanks to the development of effective treatments. Non-pharmacological approaches should be used first, focusing on lifestyle and psychosexual therapy. If required, proven effective hormonal and non-hormonal therapeutic options are available.",
keywords = "Deficiency, Estrogen, Female sexual dysfunction, Menopause, Psychosocial, Testosterone",
author = "F. Al-Azzawi and J. Bitzer and U. Brandenburg and C. Castelo-Branco and A. Graziottin and P. Kenemans and M. Lachowsky and S. Mimoun and Nappi, {R. E.} and S. Palacios and A. Schwenkhagen and J. Studd and K. Wylie and Zahradnik, {H. P.}",
year = "2010",
month = "4",
doi = "10.3109/13697130903437615",
language = "English",
volume = "13",
pages = "103--120",
journal = "Climacteric",
issn = "1369-7137",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Therapeutic options for postmenopausal female sexual dysfunction

AU - Al-Azzawi, F.

AU - Bitzer, J.

AU - Brandenburg, U.

AU - Castelo-Branco, C.

AU - Graziottin, A.

AU - Kenemans, P.

AU - Lachowsky, M.

AU - Mimoun, S.

AU - Nappi, R. E.

AU - Palacios, S.

AU - Schwenkhagen, A.

AU - Studd, J.

AU - Wylie, K.

AU - Zahradnik, H. P.

PY - 2010/4

Y1 - 2010/4

N2 - BackgroundFemale sexual dysfunction (FSD) is a multidimensional problem combining biological, psychological and interpersonal elements of multiple etiologies. Menopause-related sexual dysfunction may not be reversible without therapy. Hormonal deficiency does not usually decrease in severity over time. Many options are available for the successful treatment of postmenopausal FSD. ObjectiveTo review the pharmacological and non-pharmacological therapies available for postmenopausal FSD, focusing on practical recommendations for managing postmenopausal women with sexual complaints, through a literature review of the most relevant publications in this field. Psychosocial therapyThis type of therapy (basic counselling, physiotherapy and psychosexual intervention) is considered an adaptable step-by-step approach for diagnostic and therapeutic strategies, normally combined with biomedical interventions to provide optimal outcomes. Pharmacological therapyFor postmenopausal FSD, many interventional options are now available, including hormonal therapies such as estrogens, testosterone, combined estrogen/testosterone, tibolone and dehydroepiandrosterone. Conclusion sMenopause and its transition represent significant risk factors for the development of sexual dysfunction. FSD impacts greatly on a patient's quality of life. Consequently, it is receiving more attention thanks to the development of effective treatments. Non-pharmacological approaches should be used first, focusing on lifestyle and psychosexual therapy. If required, proven effective hormonal and non-hormonal therapeutic options are available.

AB - BackgroundFemale sexual dysfunction (FSD) is a multidimensional problem combining biological, psychological and interpersonal elements of multiple etiologies. Menopause-related sexual dysfunction may not be reversible without therapy. Hormonal deficiency does not usually decrease in severity over time. Many options are available for the successful treatment of postmenopausal FSD. ObjectiveTo review the pharmacological and non-pharmacological therapies available for postmenopausal FSD, focusing on practical recommendations for managing postmenopausal women with sexual complaints, through a literature review of the most relevant publications in this field. Psychosocial therapyThis type of therapy (basic counselling, physiotherapy and psychosexual intervention) is considered an adaptable step-by-step approach for diagnostic and therapeutic strategies, normally combined with biomedical interventions to provide optimal outcomes. Pharmacological therapyFor postmenopausal FSD, many interventional options are now available, including hormonal therapies such as estrogens, testosterone, combined estrogen/testosterone, tibolone and dehydroepiandrosterone. Conclusion sMenopause and its transition represent significant risk factors for the development of sexual dysfunction. FSD impacts greatly on a patient's quality of life. Consequently, it is receiving more attention thanks to the development of effective treatments. Non-pharmacological approaches should be used first, focusing on lifestyle and psychosexual therapy. If required, proven effective hormonal and non-hormonal therapeutic options are available.

KW - Deficiency

KW - Estrogen

KW - Female sexual dysfunction

KW - Menopause

KW - Psychosocial

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=77249177134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249177134&partnerID=8YFLogxK

U2 - 10.3109/13697130903437615

DO - 10.3109/13697130903437615

M3 - Article

C2 - 19958161

AN - SCOPUS:77249177134

VL - 13

SP - 103

EP - 120

JO - Climacteric

JF - Climacteric

SN - 1369-7137

IS - 2

ER -